News for Healthier Living

EMBARGOED: Study Reveals Activity of Navtemadlin in Glioblastoma, Points to Possible Treatment Improvements

Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy. Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage. In lab experiments, the researchers found that navtemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53.

February 19, 2025


February 21 2025

February 20 2025

February 19 2025

February 18 2025

February 17 2025

February 16 2025

February 15 2025

February 14 2025

February 13 2025

February 12 2025

February 11 2025

February 10 2025

February 9 2025

February 8 2025